SREBF1 and pachyonychia congenita: The discovery of potential therapeutic targets, such as TNK2/ACK1 or the signaling nexus pY-SREBF1/H2A-K130ac, suggests the possibility of developing new treatment strategies for PC patients, especially those affected by resistance to traditional therapies [36,37].